Basal cell carcinoma (BCC) is the most common type of skin cancer. It’s also the most commonly diagnosed cancer in the United States. Every year, millions of people learn that they have BCC.
Basal cell carcinoma that is superficial and doesn't extend very far into the skin may be treated with creams or ointments. Surgical options are Electrodesiccation and curettage (ED&C), Topical Treatment, Freezing and Mohs Surgery. Drugs options, imiquimod (Aldara) and fluorouracil (Efudex, Fluoroplex, others) are used for several weeks to treat such low-risk basal cell carcinomas. Basal cell carcinoma that spreads to other areas of the body (metastasizes) may be treated with vismodegib (Erivedge) or sonidegib (Odomzo).
Market Analysis and Insights: Global Basal Cell Carcinoma Treatment Market
Due to the COVID-19 pandemic, the global Basal Cell Carcinoma Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type accounting for % of the Basal Cell Carcinoma Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Type segment is altered to an % CAGR throughout this forecast period.
The classification of Basal Cell Carcinoma Treatment includes Topical Treatment, Hedgehog Pathway Inhibitor Therapy, Mohs Surgery, Other Surgeries and Other Treatments, and the proportion of Topical Treatment in 2018 is about 30.4%. Basal Cell Carcinoma Treatment is widely used in Hospitals, Specialty Clinics and other field. The most proportion of Basal Cell Carcinoma Treatment is Hospitals, and the sales proportion in 2018 is 53.2%. Market competition is intense. Roche, Sun Pharmaceuticals, Bausch Health Companies, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Global Basal Cell Carcinoma Treatment Scope and Market Size
The global Basal Cell Carcinoma Treatment market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Basal Cell Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Segment by Type
Topical Treatment
Hedgehog Pathway Inhibitor Therapy
Mohs Surgery
Other Surgeries
Other Treatments
Segment by Application
Hospitals
Specialty Clinics
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Roche
Sun Pharmaceuticals
Bausch Health Companies
Taro Pharmaceuticals
Mylan
Basal cell carcinoma that is superficial and doesn't extend very far into the skin may be treated with creams or ointments. Surgical options are Electrodesiccation and curettage (ED&C), Topical Treatment, Freezing and Mohs Surgery. Drugs options, imiquimod (Aldara) and fluorouracil (Efudex, Fluoroplex, others) are used for several weeks to treat such low-risk basal cell carcinomas. Basal cell carcinoma that spreads to other areas of the body (metastasizes) may be treated with vismodegib (Erivedge) or sonidegib (Odomzo).
Market Analysis and Insights: Global Basal Cell Carcinoma Treatment Market
Due to the COVID-19 pandemic, the global Basal Cell Carcinoma Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type accounting for % of the Basal Cell Carcinoma Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Type segment is altered to an % CAGR throughout this forecast period.
The classification of Basal Cell Carcinoma Treatment includes Topical Treatment, Hedgehog Pathway Inhibitor Therapy, Mohs Surgery, Other Surgeries and Other Treatments, and the proportion of Topical Treatment in 2018 is about 30.4%. Basal Cell Carcinoma Treatment is widely used in Hospitals, Specialty Clinics and other field. The most proportion of Basal Cell Carcinoma Treatment is Hospitals, and the sales proportion in 2018 is 53.2%. Market competition is intense. Roche, Sun Pharmaceuticals, Bausch Health Companies, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Global Basal Cell Carcinoma Treatment Scope and Market Size
The global Basal Cell Carcinoma Treatment market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Basal Cell Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Segment by Type
Topical Treatment
Hedgehog Pathway Inhibitor Therapy
Mohs Surgery
Other Surgeries
Other Treatments
Segment by Application
Hospitals
Specialty Clinics
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Roche
Sun Pharmaceuticals
Bausch Health Companies
Taro Pharmaceuticals
Mylan
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.